Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers

Khoshghamat, Negar; Jafari, Niloufar; Moetamani‐Ahmadi, Mehrdad; Khalili-Tanha, Ghazaleh; rad, Mohammad-Hossein Khajavi; Sahebdel, Saeed; Khalili-Tanha, Nima; Soleimanpour, Saman; Khazaei, Majid; Hassanian, Seyed Mahdi; Ferns, Gordon A.

doi:10.1016/j.prp.2021.153390

Cited by 3 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in esophageal squamous cell carcinoma cases, PD-L1 expression is more frequent in tumor cells rather than in immune or stromal cells 34 . The value of PD-L1 expression as a prognostic biomarker is still controversial 38 .…”

Section: Pd-l1 In Gastroesophageal Cancersmentioning

confidence: 99%

PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application

et al. 2022

View full text Add to dashboard Cite

Summary Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical benefit in many solid cancer types, including gastrointestinal malignancies. However, it has been estimated that only 20-40% of patients respond to treatment. The pattern of expression and potential predictive value of PD-L1 as an immunohistochemical biomarker has been extensively studied in gastrointestinal neoplasms. Until now, its predictive value has been demonstrated, and is currently in use only in upper gastrointestinal malignancies (gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma). In this Review, we describe the technical aspects and challenges related to PD-L1 immunohistochemical assays, the current role of PD-L1 as a biomarker in clinical practice and we outline the main studies and clinical trials analyzing the prognostic and predictive value of PD-L1 in gastrointestinal cancers.

show abstract

Section: Pd-l1 In Gastroesophageal Cancersmentioning

confidence: 99%